←Back to Expert Scholars
Translational Medicine / 转化医学AML Novel Targets, Clinical Trials
Farhad Ravandi
MD
🏢MD Anderson Cancer Center🌐USA
Professor of Leukemia
90
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Farhad Ravandi leads AML clinical trials at MD Anderson and has led pivotal studies of gemtuzumab ozogamicin, CPX-351, and FLT3 inhibitors. He has contributed to multiple approvals in AML and pre-leukemia. His work continues to shape standard and investigational AML therapy.
Share:
🧪Research Fields 研究领域
AML
FLT3 inhibitors
CPX-351
gemtuzumab ozogamicin
novel AML agents
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Farhad Ravandi 的研究动态
Follow Farhad Ravandi's research updates
留下邮箱，当我们发布与 Farhad Ravandi（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment